inflammatory bowel disease
Data from several presentations at the American Society of Human Genetics annual meeting demonstrated the benefits of using diverse ancestries in human genetic studies.
Adaptive Biotechnologies Halts T-Detect Commercialization, Reports 13 Percent Q2 Revenue Growth
Premium
The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.
Boehringer Ingelheim, BiomX Embark on New Inflammatory Bowel Disease Biomarker Discovery Project
The deal is the second of its kind for the two companies following a 2020 partnership to investigate metagenomic markers of different IBD patient phenotypes.
Although it has seemingly tried to do everything, everywhere, all at once with its immune sequencing technology, Adaptive has sharpened its focus.
The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.